The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Overview of the RATIFY study: midostaurin combination therapy for AML
In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III RATIFY study (NCT00651261) of daunorubicin, cytarabine and midostaurin for the treatment of newly diagnosed acute myeloid leukemia (AML). Dr Stone highlights the implications of this regimen for the treatment of FLT3-mutated AML. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
